<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172688</url>
  </required_header>
  <id_info>
    <org_study_id>REB17-2363</org_study_id>
    <nct_id>NCT04172688</nct_id>
  </id_info>
  <brief_title>Effect of Prebiotics on Function and Pain in Patients With Osteoarthritis and Obesity Obesity</brief_title>
  <official_title>Effect of Prebiotics on Function and Pain in Patients With Knee Osteoarthritis and Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to determine if prebiotic supplementation can, through
      changes in the intestinal gut microbiota, lead to improvements in knee function and physical
      performance and reduce knee pain in adults with obesity and idiopathic metabolic knee
      osteoarthritis. We hypothesize that prebiotics will reduce systemic and local (knee joint)
      inflammation, thus improving knee function, lower pain medication use, and enhance
      performance of daily life activities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome:

      1. To determine the change in knee joint function and physical performance in adults with
      obesity and knee osteoarthritis treated for 6 months with oligofructose-enriched inulin or
      placebo.

      Secondary outcomes:

        1. To determine the change in knee pain in adults with obesity and knee osteoarthritis
           treated for 6 months with oligofructose-enriched inulin or placebo.

        2. To examine the change in body composition (fat mass and lean mass) in participants
           treated with oligofructose-enriched inulin or placebo.

        3. To evaluate the change in quality of life in participants treated with
           oligofructose-enriched inulin or placebo.

        4. To gain a mechanistic understanding of the influence of oligofructose-enriched inulin
           supplementation in metabolic OA through examination of gut microbiota composition and
           short-chain fatty acid concentrations.

        5. To gain a mechanistic understanding of the influence of oligofructose-enriched inulin
           supplementation in metabolic OA through examination of serum inflammatory and
           metabolomics markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 30 second chair stand test</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>30 second chair stand test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 40 metre fast based walk</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>40 metre fast based walk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Time up and go test</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Time up and go test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6 minute walk test</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>6 minute walk test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in knee function</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Knee extensor torque isokinetic dynamometer (Biodex System3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in knee pain</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Numerical Pain Rating Scale (NPRS) for Knee Pain (0-10 scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in knee injury and osteoarthritis outcome score (KOOS)</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>KOOS questionnaire (42 items in 5 separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL).)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain medication use</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Pain medication questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body fat</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Body fat percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal microbiota composition</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Fecal microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal short chain fatty acids (SCFA) concentration</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Fecal SCFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum endotoxin</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Serum LPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum inflammatory marker</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Serum IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physical activity level</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>ActiGraph LinkÂ® accelerometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life ratings</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>SF-36 Quality of Life Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum metabolomics</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Serum LC-Qtof-Mass Spec metabolomics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in gastrointestinal comfort</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Gastrointestinal Feelings Questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two 3.3g doses/day (12 kcal/dose) of maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 8g doses/day (12 kcal/dose) of oligofructose-enriched inulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic oligofructose-enriched inulin</intervention_name>
    <description>Synergy1</description>
    <arm_group_label>Prebiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo maltodextrin</intervention_name>
    <description>Equicaloric dose of maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults aged 30-75 years of age.

          -  BMI greater than 30kg/m2.

          -  Diagnosis via x-ray of knee OA grade II and III (Kellgren and Lawrence).

        Exclusion Criteria:

          -  Knee OA resulting from a traumatic injury.

          -  Previous knee surgery.

          -  Concomitant use of any weight loss medication, previous bariatric or other intestinal
             surgery

          -  Presence of active infection, pregnancy or lactation.

          -  Regular use of a probiotic or prebiotic supplement within 3 months prior to
             enrollment.

          -  Antibiotic use within 3 months prior to enrollment

          -  Uncontrolled cardiovascular or respiratory disease, active malignancy, or chronic
             infections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raylene A Reimer, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raylene A Reimer, PhD, RD</last_name>
    <phone>403-220-8218</phone>
    <email>reimer@ucalgary.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raylene A Reimer, PhD, RD</last_name>
      <phone>403-220-8218</phone>
      <email>reimer@ucalgary.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Raylene Reimer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Prebiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

